Sunbio Corporation – Trademark Portfolio
Entity Type: 03
Sunbio Corporation holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include BOMME, ESTROG, NC-518, ESTROG-100, and DECURSINOL-50. The owner is based in Carlsbad, CA.
1606 Bittern Ct
Carlsbad, CA 92011
Showing of trademarks Trademarks
Trademark Classifications
Sunbio Corporation's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Sunbio Corporation have?
Sunbio Corporation has 10 U.S. trademarks filed with the USPTO. Of these, 5 registered, 2 abandoned, 3 cancelled.
What trademark classes does Sunbio Corporation file in?
Sunbio Corporation files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Sunbio Corporation's most well-known trademarks?
Sunbio Corporation's registered trademark portfolio includes well-known marks such as BOMME, ESTROG, NC-518, ESTROG-100, and DECURSINOL-50. These are among 5 currently registered trademarks in the portfolio.
What is Sunbio Corporation's trademark registration success rate?
Sunbio Corporation has a 50% trademark registration rate, with 5 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.